DO, FCAP, FASCP
Chief Medical Officer of Genomic and Clinical Pathology
Dr. Chandra joined PathGroup in 2011 as Associate Medical Director of Molecular Pathology and now currently serves as Chief Medical Officer of Genomic and Clinical Pathology Services at PathGroup. Dr. Chandra holds board certifications in anatomic and clinical pathology, hematopathology and molecular genetic pathology. He completed his AP/CP training and fellowships in hematopathology, oncologic pathology and molecular pathology at NYU Langone Medical Center and the University of Texas-MD Anderson Cancer Center, respectively. While at MD Anderson, he served as Chief Fellow and received numerous awards for his research in acute myeloid leukemia. He has presented numerous abstracts and platform presentations at various pathology meetings and has published peer-reviewed articles and book chapters. Dr. Chandra is a member of the American Society of Clinical Pathology, Association of Molecular Pathology where he also serves in a leadership capacity to the Economic Affairs and Clinical Practice Committees. Dr. Chandra is a medical consultant in molecular pathology and personalized medicine and is considered a national thought leader in Precision Medicine and Cancer Genomics.
Chair of Pathology
University of Florida School of Medicine
Dr. Clare-Salzler received his medical degree and internal medicine training from the State University of New York at Buffalo. He began his clinical endocrinology and immunology research career at the University of California in Los Angeles, where he studied the immunopathogenesis of type 1 diabetes. Dr. Clare-Salzler maintains an active practice in endocrinology, treating patients with diabetes and other endocrine diseases as well as an active research program. He has also played a leadership role in the development of the clinical molecular pathology laboratory and the Precision Medicine program at Florida.
Professor and Chair, Pathology and Laboratory Medicine
Donald and Barbara Zucker School of Medicine
Great Neck/Hempstead, NY
Dr. Crawford oversees the integrated laboratory network for Northwell Health, which includes 23 hospital-based clinical laboratories; the health system’s integrated pathology practice; and the centralized Core Laboratory that serves Northwell and, through the CLNY Alliance, the 15 hospitals of Health + Hospitals of New York City.
Dr. Crawford is a leading proponent of the role of pathology and the clinical laboratory industry in patient-centered care and value-based care. He is providing national leadership in developing the value statements for laboratory diagnostic services, which includes being founding member of Project Santa Fe and the concept of “Clinical Laboratory 2.0.” The latter’s goal is for clinical laboratories to support a proactive, integrative paradigm of health care, taking particular advantage of the vast store of latent information in the data routinely generated through clinical laboratories. This is then coupled with opportunities in precision medicine, as through genomics, biobanking and informatics.
Author of more than 260 publications, Dr. Crawford is editor-in-chief of Academic Pathology, the official journal of the Association of Pathology Chairs (APC). He received his MD and PhD from Duke University School of Medicine, and he completed post-graduate training in anatomic pathology and gastrointestinal pathology at Brigham and Women's Hospital, followed by a fellowship in hepatic pathology at the Royal Free Hospital in London.
Donald and Barbara Zucker School of Medicine
Member, College of American Pathology
Personalized Medicine Committee
New Hyde Park, NY
Dr. Laser is a board certified anatomic, clinical and molecular genetic pathologist. Currently employed at Northwell Health System in New York, Dr. Jordan serves the Department of Pathology and Laboratory Medicine in the following roles: Medical Director, LIJ Pathology and Laboratory Medicine; Associate Medical Director, Core Laboratories, Senior Director, Division of Cytogenetics and Molecular Pathology; and Director, Division of Near Patient Testing. His expertise includes, molecular and genomic medicine, laboratory management, healthcare finance and standards and regulations.
Director of Strategic Initiatives
Plymouth Meeting, PA
Dr. Nelson-Nichols works closely with executive leadership to identify, explore, and execute on opportunities that support ECRI’s mission to advance effective, evidence-based healthcare globally.
Dr. Nelson-Nichols joined ECRI in July 2011 as a senior clinical writer for an online horizon-scanning database that predicts potential impacts of up-and-coming healthcare technologies. In June 2014, she transitioned from an internal role as a content team leader to an external role working directly with members of ECRI’s Health Technology Assessment (HTA) Service to support health systems and third-party payers in their use of ECRI’s evidence tools to inform decision making about healthcare technology adoption, implementation, and coverage. In 2017, Dr. Nelson-Nichols took on a more strategic role as Assistant Director of ECRI’s HTA and ECRIgene Services. She continued to work directly with members in the field while participating in product and new business development, marketing strategies, and undertaking speaking engagements.